RU2017109086A - Прогностический маркер hf - Google Patents

Прогностический маркер hf Download PDF

Info

Publication number
RU2017109086A
RU2017109086A RU2017109086A RU2017109086A RU2017109086A RU 2017109086 A RU2017109086 A RU 2017109086A RU 2017109086 A RU2017109086 A RU 2017109086A RU 2017109086 A RU2017109086 A RU 2017109086A RU 2017109086 A RU2017109086 A RU 2017109086A
Authority
RU
Russia
Prior art keywords
vitro method
nep
soluble
vitro
level
Prior art date
Application number
RU2017109086A
Other languages
English (en)
Russian (ru)
Other versions
RU2017109086A3 (enExample
Inventor
ХЕНИС Антони БАЙЕС
РОСЕС Хосеп ЛУПОН
ОРТЕГА Ампаро ГАЛАН
МАРТИНЕС ДЕ ОСАБА Хауме БАРАЛЬЯТ
Original Assignee
Фундасио Институт Д'Инвестигасио Эн Сьенсьес Де Ла Салут Херманс Триас И Пухоль
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фундасио Институт Д'Инвестигасио Эн Сьенсьес Де Ла Салут Херманс Триас И Пухоль filed Critical Фундасио Институт Д'Инвестигасио Эн Сьенсьес Де Ла Салут Херманс Триас И Пухоль
Publication of RU2017109086A publication Critical patent/RU2017109086A/ru
Publication of RU2017109086A3 publication Critical patent/RU2017109086A3/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96497—Enkephalinase (3.4.24.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
RU2017109086A 2014-08-29 2015-08-14 Прогностический маркер hf RU2017109086A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14182846.7 2014-08-29
EP14182846.7A EP2990800A1 (en) 2014-08-29 2014-08-29 Neprilysin as heartfailure (HF) prognostic marker
PCT/EP2015/068729 WO2016030209A1 (en) 2014-08-29 2015-08-14 Neprilysin as heart failure prognostic marker

Publications (2)

Publication Number Publication Date
RU2017109086A true RU2017109086A (ru) 2018-10-01
RU2017109086A3 RU2017109086A3 (enExample) 2019-03-06

Family

ID=51421966

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017109086A RU2017109086A (ru) 2014-08-29 2015-08-14 Прогностический маркер hf

Country Status (11)

Country Link
US (1) US10203341B2 (enExample)
EP (2) EP2990800A1 (enExample)
JP (1) JP6661216B2 (enExample)
CN (1) CN107076758B (enExample)
AU (1) AU2015309112A1 (enExample)
CA (1) CA2959094A1 (enExample)
ES (1) ES2734876T3 (enExample)
MX (1) MX2017002453A (enExample)
RU (1) RU2017109086A (enExample)
SG (1) SG11201701393YA (enExample)
WO (1) WO2016030209A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12699104B2 (en) 2019-11-06 2026-08-04 National University Corporation Kagawa University Heart failure marker

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020762A1 (en) * 2001-09-03 2003-03-13 Intreat Pty Limited Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions
MX340078B (es) * 2009-11-07 2016-06-24 Astute Medical Inc Metodos y composiciones para el diagnostico y pronostico de daño renal y falla renal.
EP2360280A1 (en) * 2010-02-24 2011-08-24 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Genetic marker for the diagnosis of dementia with Lewy bodies
JP2014505259A (ja) * 2011-02-03 2014-02-27 アボット・ラボラトリーズ 慢性心不全における予後診断および診断の方法
IN2014MN02101A (enExample) * 2012-04-12 2015-08-28 Brahms Gmbh
RU2667643C2 (ru) * 2012-08-24 2018-09-21 Новартис Аг Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия
US20140206632A1 (en) 2013-01-22 2014-07-24 Singulex, Inc. Endothelin in the Diagnosis of Cardiac Disease
WO2014126972A1 (en) * 2013-02-14 2014-08-21 Novartis Ag Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy
SG11201506018PA (en) * 2013-02-14 2015-08-28 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors

Also Published As

Publication number Publication date
CA2959094A1 (en) 2016-03-03
EP3186639A1 (en) 2017-07-05
US10203341B2 (en) 2019-02-12
CN107076758A (zh) 2017-08-18
SG11201701393YA (en) 2017-03-30
JP2017526924A (ja) 2017-09-14
MX2017002453A (es) 2017-10-23
WO2016030209A1 (en) 2016-03-03
AU2015309112A1 (en) 2017-04-06
ES2734876T3 (es) 2019-12-12
CN107076758B (zh) 2019-10-22
US20170254815A1 (en) 2017-09-07
EP3186639B1 (en) 2019-03-20
EP2990800A1 (en) 2016-03-02
JP6661216B2 (ja) 2020-03-11
RU2017109086A3 (enExample) 2019-03-06

Similar Documents

Publication Publication Date Title
AR103935A1 (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2
BR112014006741A2 (pt) método para monitorização, diagnóstico e/ou prognóstico de lesão renal aguda no estágio inicial
JP2015519564A5 (enExample)
NZ619883A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
RU2011125320A (ru) Способы, устройства и наборы для детекции или мониторинга острого повреждения почек
Qin et al. Discovery of non-invasive glycan biomarkers for detection and surveillance of gastric cancer
WO2014144129A3 (en) Biomarkers and methods for predicting preterm birth
WO2014143977A3 (en) Biomarkers and methods for predicting preeclampsia
EA200971114A1 (ru) Определение антигенов, расположенных на эритроцитах, и антиэритроцитарных антител
RU2015148193A (ru) Биомаркеры для прогнозирования и оценки чувствительности субъектов с раком эндометрия к соединениям ленватиниба
PE20210042A1 (es) Metodos para detectar transtiretina
MX2020009705A (es) Metodos para la deteccion del riesgo de enfermedad renal cronica en un sujeto y metodo implementado por computadora.
JP2017532577A5 (enExample)
JP2017500584A5 (enExample)
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
JP2017505897A5 (enExample)
RU2015104737A (ru) Способ обнаружения мультиспецифического связывающего агента
NZ599773A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Gandhi et al. Analysis of BAG3 plasma concentrations in patients with acutely decompensated heart failure
Li et al. Utility of cystatin C-based equations in patients undergoing dialysis
JP2017524933A5 (enExample)
WO2012021741A3 (en) Lateral flow assays for non-diagnostic analytes
CN106796221A (zh) 川崎氏症的诊断与治疗
JP2015528562A5 (enExample)
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20191223